Over the past few years, nitrosamines and cohorts of concern (CoC) have emerged as the most critical safety issue in small molecule APIs and finished pharmaceutical products. Regulatory authorities worldwide require comprehensive risk evaluations from all marketing authorization holders.
Sources of Nitrosamine Contamination
Nitrosamines (such as NDMA, NDEA, NMBA, and complex NDSRIs) typically form when secondary or tertiary amines react with a nitrosating agent (e.g., nitrites) under acidic conditions. Common formation vectors include:
- Raw materials, starting materials, and recovered solvents containing trace sodium nitrite.
- Excipients carrying trace levels of nitrites or nitrates as contaminants.
- Degradation of drug substances during stability storage under elevated temperature and humidity.
- Primary packaging materials such as nitrocellulose lidding foil.
The 3-Step Regulatory Compliance Workflow
- Step 1: Risk Assessment: Evaluate the chemical synthesis, raw materials, water, packaging, and shelf-life stability to identify theoretical risk of nitrosamine presence.
- Step 2: Confirmatory Testing: Where risk cannot be ruled out, perform trace-level quantitation using validated LC-MS/MS or GC-MS/MS methods capable of sub-ppm or ppb limits of quantitation (LOQ).
- Step 3: Regulatory Reporting & Remediation: Update drug master files (DMF/CEP), reformulate with nitrite scavengers, or modify synthesis routes if levels exceed acceptable intake (AI).
How KemQuest Supports Nitrosamine Profiling
KemQuest Pharma Services provides end-to-end analytical testing support, protocol drafting, and risk assessment consultancy to ensure compliance with US FDA, EMA, and CDSCO directives.